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Background: There is converging preclinical and clinical evidence to suggest that the extracellular signal-regulated
kinase (ERK) signaling pathway may be dysregulated in autism spectrum disorders.
Method: We evaluated Mapk/Erk1/2, cellular proliferation and apoptosis in BTBR mice, as a preclinical model of
Autism. We had previously generated 410 F2 mice from the cross of BTBR with B6. At that time, six different social
behaviors in all F2 mice were evaluated and scored. In this study, eight mice at each extreme of the social behavioral
spectrum were selected and the expression and activity levels of Mapk/Erk in the prefrontal cortex and cerebellum of
these mice were compared. Finally, we compared the Mapk/Erk signaling pathway in brain and lymphocytes of the
same mice, testing for correlation in the degree of kinase activation across these separate tissues.
Results: Levels of phosphorylated Erk (p-Erk) were significantly increased in the brains of BTBR versus control mice. We
also observed a significant association between juvenile social behavior and phosphorylated mitogen-activated protein
kinase kinase (p-Mek) and p-Erk levels in the prefrontal cortex but not in the cerebellum. In contrast, we did not find a
significant association between social behavior and total protein levels of either Mek or Erk. We also tested whether
steady-state levels of Erk activation in the cerebral cortex in individual animals correlated with levels of Erk activation in
lymphocytes, finding a significant relationship for this signaling pathway.
Conclusion: These observations suggest that dysregulation of the ERK signaling pathway may be an important
mediator of social behavior, and that measuring activation of this pathway in peripheral lymphocytes may serve as a
surrogate marker for central nervous system (CNS) ERK activity, and possibly autistic behavior.Background
Autism spectrum disorders (ASD) are defined by the dis-
ruption of language and social function and self-stimulatory
or repetitive behaviors. The etiologic heterogeneity of ASD
has complicated progress towards understanding the bio-
logical mechanisms of autism and developing targeted
therapies. Recently, however, advances in autism genetics
and progress in the study of animal models have provided
evidence to suggest that some intracellular pathways are
commonly affected in autistic patients, particularly the
mitogen-activated protein kinase (MAPK)/extracellular
signal-related kinase (ERK) pathway [1]. Genome-wide as-
sociation studies [2] and genomic copy number variant
(CNV) analyses have identified enrichment in gene-sets* Correspondence: sherre@neuropeds.ucsf.edu
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unless otherwise stated.involved in RAS (Rat Sarcoma)/MAPK signaling and
kinase activation in ASD individuals [3]. Interestingly, a 593-
kb deletion in chromosome 16p11.2, one of the most com-
mon CNVs associated with autism, contains the MAPK3
(ERK1) gene [4,5]. In addition, a number of single-gene
mutations implicated in syndromes such as “RASopathy”
disorders [1], fragile X syndrome [6], and tuberous scler-
osis [7,8], are also associated with disruption of the RAS/
MAPK signaling pathway and lead to pleiotropic neuro-
cognitive impairments, including ASD [1]. Furthermore,
in mice, inactivation of Mapk(Erk2) in the forebrain re-
sults in alterations in behavior that have similarities with
those seen in autism [9]. These findings provide prelimin-
ary evidence that regulation of ERK signaling may be
broadly altered in autism.
The RAS/MAPK signaling pathway mediates the trans-
mission of signals from cell surface receptors to cytoplas-
mic and nuclear effectors. Diverse groups of molecularThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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1) and initiate downstream signaling through ERK [1].
Depending on enzyme kinetics, and sub-cellular distribu-
tion of each component, this pathway will mediate diverse
cellular functions including proliferation, migration, differ-
entiation, and cell survival [10]. In the nervous system,
this pathway is additionally involved in a diverse array of
activity-dependent neuronal events, including synaptic
plasticity, long-term potentiation or depression (LTP and
LTD), and memory formation [9,11]. For example, in the
transgenic mouse model of tuberous sclerosis, dysregu-
lated ERK leads to impaired LTD, which was shown to
mediate social behavioral deficits [7].
Recently, the inbred mouse strain BTBR T + tf/J (BTBR)
has been studied as a possible preclinical model of autism
[12], and we have recently shown that these behaviors are
quantitatively linked to genetic loci [13]. A total of six
quantitative trait loci, meeting genome-wide significance
for three autism relevant behaviors in BTBR, were identi-
fied on chromosomes 1, 3, 9, 10, 12, and X. Moreover, in a
recently published biochemical evaluation of BTBR mice,
the authors identified upregulation of the ERK signaling
pathway in the newborn mice, suggesting, but not demon-
strating directly, that this elevation in Erk activation was
linked with the autistic behavior in BTBR [14]. In this
current study we evaluated the Ras/Mapk signaling path-
way in BTBR mice, and tested whether there was a correl-
ation between the degree of activation of the Ras/Mapk
pathways and autism-relevant traits, by testing inter-
crossed mice that all share varying degrees of the BTBR
genome, allowing a stratified comparison of Erk activation
and behavior. We also assessed whether levels of Erk acti-
vation in the brain correlated with levels of Erk activation
in lymphocytes from the same animal. Both these lines of
investigation provide preliminary evidence for the role of
ERK activation in models of ASD and the capacity to
monitor this activation in peripheral tissue.
Methods
Mice
BTBR, CD1 and C57BL/6 J (B6) lines were sourced from
the Jackson Laboratory (Bar Harbor, Maine, United States).
Mice from the same strain were bred either on site at the
University of California, San Francisco or at The University
of Queensland, under ethics approval from the respective
University Animal Ethics Committees. Mice were weaned
at P (postnatal day) 20 to 23 and then group-housed by sex
in standard mouse cages containing two to four mice, fol-
lowing standard protocol. The day of vaginal plug was
designated as E (embryonic day) 0 and the day of delivery
as P0. BTBR and B6 were also bred and a total of 410 F2
mice were generated for behavioral testing over a period
of two years in the laboratory of Dr Jacqueline Crawley at
the NIMH (National Institute of Mental Health) inBethesda, Maryland. The first cohort of 204 mice was gen-
erated by crossing F1 males and females derived from
BTBR female and B6 male matings. The second cohort of
206 mice was generated by the reciprocal cross of F1
males and females derived from B6 female and BTBR
male matings. This ensured equal representation of the
BTBR and B6 X chromosomes in the final F2 cohort. Fur-
ther details have been described previously [13].
Autism-relevant behaviors evaluated in F2 mice
Juvenile reciprocal social interactions were assessed on
P21. The test mouse and age- and sex-matched B6 con-
trol mice were simultaneously placed in the field and
their interactions were videotaped for 10 minutes. Social
behaviors including nose-to-nose sniff (sniffing the nose
and snout region of the partner), front approach (moving
towards the partner, in a head-on manner), and push-crawl
(pushing the head underneath the partner’s body or squeez-
ing between the wall or floor and the partner, and crawling
over or under the partner’s body, combined as a single par-
ameter) were evaluated and scored by a highly trained ob-
server, using the Noldus Observer 5.0 software (Noldus
Information Technology Wageningen, Netherlands).
Social approach was assayed in automated three-
chambered apparatus between eight and 12 weeks of
age. The test mouse was briefly confined to the center
chamber while the clean novel object was placed in one
of the side chambers. A novel mouse, previously habitu-
ated to the enclosure, was placed in an identical wire
cup located in the other side chamber. The side contain-
ing the novel object and the novel mouse alternated be-
tween the left and right chambers across subjects. After
both stimuli were positioned, the two side doors were
simultaneously lifted and the subject was allowed access
to all three chambers for 10 minutes. Number of entries
and time spent in each of the three chambers were auto-
matically detected by photocells embedded in the doorways
and tallied by the software. In addition, time spent sniffing
the novel mouse was scored by human observers [13].
Protein extraction from mouse tissues and lymphocytes
P0 and P30 BTBR and B6 mice were euthanized by ad-
ministration of inhaled CO2 followed by cervical disloca-
tion. Whole brains were extracted and homogenized
in ice-cold NP-40 lysis buffer containing 50 mM Tris
(pH 7.5), 150 mM NaCl, 20 mM MgCl2, and 0.5%
NP-40 with the addition of protein phosphatase in-
hibitor (PhosSTOP, Product number: 04906845001, Roche
Diagnostics, Indianapolis, USA) and protease inhibitor
cocktails (Complete Protease Inhibitor, Product number:
11697498001, Roche Diagnostics, Indianapolis, United
states). After centrifugation (13,000 x-g, 15 minutes, 4°C),
the supernatants were collected. The protein concentra-
tion was measured using the Bio-Rad protein assay (Life
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stored at −80°C.
Three-month-old F2 offspring from a cross of BTBR
and B6 mice were anesthetized with ketamine and xyla-
zine then perfused with phosphate buffered saline (PBS)
and fixed with 4% paraformaldehyde via cardiac punc-
ture, and the brains were extracted. One hemisphere
was used for anatomic evaluation and proteins were iso-
lated from the prefrontal cortex and cerebellum of the
other hemisphere using the Qproteome FFPE kit (Qiagen,
Hilden, Germany) [15].
To extract protein from lymphocytes, the spleens of the
mice were removed and mechanically meshed through a
cell strainer. Cells were washed with PBS and then 2 to
3 μl of red blood cell (RBC) lysis buffer (Biolegend, San
Diego, USA) was added to the cell aliquot for 2 minutes
to lyse the RBCs, and the remaining lymphocytes were
pelleted and washed. Subsequently, NP-40 lysis buffer was
added to the cell aliquot and the cellular extract subjected
to centrifugation. The extracted protein supernatant was
stored at −80°C.
Protein electrophoresis and Western blot analysis
Samples were denatured in sample buffer by heating at
95°C for 5 minutes. A total of 20 micrograms of protein
per lane was run on a 12% acrylamide gel for 2 hours at
100 V. The proteins were transferred to a PVDF membrane
at 50 V for 1 hour and the PVDF membrane (Bio-RAD, Life
Science Research, Hercules, USA) was then blocked for
1 hour with 5% dry milk in PBS with 0.1% Tween 20.
Thereafter, the primary antibodies were applied overnight
with continuous shaking at 4°C. The primary antibodies
included rabbit mAb Ras, Phospho-mitogen-activated
protein kinase kinase (MEK)1/2 (Ser217/221), rabbit mAb
MEK1/2 (47E6), rabbit mAb Phospho-ERK (Thr 202/Tyr
204), p44/42 MAPK(ERK1/2), rabbit mAb β-actin (Cell
Signaling). The blots were then washed and incubated
with secondary antibody, HRP (Horseradish peroxidase)
-linked anti-rabbit IgG, (Cell Signaling) for 1 hour at room
temperature. Immunoreactive bands were visualized by
using the enhanced chemiluminescence detection system
(Pierce) and exposed to autoradiography film (HyBlot film
CL). Densitometry was performed using ImageJ software,
based on the standard protocol described via the National
Institutes of Health (Bethesda, Maryland, United States).
The intensity of the each protein is normalized to the
actin signal obtained after stripping the same membrane
and reprobing for actin in the same lane.
Immunohistochemical analysis of cellular proliferation
Pregnant BTBR and control CD1 dams (n ≥6) were given an
intraperitoneal injection of 5-Ethynyl-2′-deoxyuridine (EdU,
10 μg per kg of body weight, Invitrogen, Life Technologies,
Grand Island, NY, USA) 30 minutes prior to sacrifice.Dams were then anesthetized with ketamine and xyla-
zine and embryos collected at E14 and E17. E14 heads
were immersion fixed in 4% paraformaldehyde (4%
PFA) w/v in PBS pH7.4 (ProSciTech, Kirwan Australia),
whilst E17 embryos were transcardially perfused with
saline (0.9% NaCl w/v in H2O) followed by 4% PFA.
Brains were extracted and sectioned at 50 μm thickness on
the coronal orientation using a vibratome. Representative
sections of the rostral telencephalon were mounted, post-
fixed with 4% PFA for 20 minutes, and subjected to sodium
citrate antigen retrieval (125°C at 15 psi for 4 minutes
in sodium citrate buffer, 10 mM C6H5Na3O7, 2H2O,
and 0.05% v/v Tween 20 in MilliQTM H2O, at pH 6.0).
Sections were blocked in normal goat serum (10%)/
0.2% Triton-X (Sigma-Aldrich, St Louis, Missouri,
United States) in PBS for 30 minutes. EdU detection
was performed using a Click-IT EdU Alexa Fluor 488
Imaging Kit (Invitrogen, Life Technologies, Grand Is-
land, NY, USA), according to the manufacturer’s in-
structions. The slides were then light protected and re-
blocked in 10% normal goat serum/0.2% Triton-X 100
in PBS for 2 hours. The following primary antibodies
were applied to the slides in the blocking solution and
left overnight: rabbit anti-phospho-histone H3 (Ser 10,
1:500, EMD Millipore, Darmstadt, Germany), rabbit anti-
Pax6 (1:500, EMD Millipore, Darmstadt, Germany),
rabbit anti-TBR2 (1:500, Abcam, Cambridge, USA)
mouse anti-human Ki67 (1:500, BD Biosciences, San
Jose, USA). After PBS washes, sections were then incu-
bated for 3 hours with Alexa Fluor 555 donkey anti-
rabbit IgG (1:500, Invitrogen, Life Technologies, Grand
Island, NY, USA)) secondary antibody. Biotinylated don-
key anti-mouse IgG (1:500, Jackson ImmunoResearch,
West Grove, USA) was then applied for 1 hour. Following
further PBS washes, Alexa Fluor 647 Streptavidin conju-
gate (1:500, Invitrogen Life Technologies, Grand Island,
NY, USA)) was applied for one hour. Slides were counter-
stained with nuclear marker DAPI (diamidino-2-phenylin-
dole) (1:1000, Invitrogen, Life Technologies, Grand Island,
NY, USA), washed and cover-slipped with ProLong Gold
(Invitrogen Life Technologies, Grand Island, NY, USA).
Images were obtained at 20x magnification in a single
representative z-plane using an inverted spinning disk
confocal microscope equipped with Hamamatsu Flash4.0
scientific CMOS camera (Hamamatsu, Japan) and ac-
quired with Slidebook (3i Intelligent Imaging Innovations,
Denver, USA). Images were pseudo-colored for presenta-
tion in Adobe Photoshop (Adobe Systems Incorporated,
San Jose, United States).
Quantification of cellular proliferation
Cell counts were performed on a region of interest from
the neocortex, midline, and ganglionic eminence automat-
ically using the spot analysis module in Imaris (Bitplane,
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Figure 1 Study design. A and B) Intercrosses of BTBR and C57BL/6
mice were performed to produce F2 mice that have a mixed
genetic background. C) Each juvenile and adult social behavior was
evaluated and quantified in all 410 F2 mice. Mice with the lowest
and highest scores of each social behavior were selected and Mapk/
Erk activity in the prefrontal cortex and cerebellum were evaluated.
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for detection of positive cells for each marker but kept
constant between control and BTBR groups. Absolute
cell counts were imported into Prism v.6 (GraphPad,
La Jolla, USA) and presented as mean ± standard error.
Statistical significance was determined at P <0.05, using
the Mann-Whitney U test.
Statistical analysis
All data are shown as mean ± SEM. Group comparisons
are analyzed using the non- parametric Mann-Whitney
U test, using GraphPad Prism v.6 (P <0.05 was consid-
ered statistically significant). Non-parametric correlation
(Spearman correlation) was also conducted to compare
paired measurements of Mapk/Erk levels in the brain
and lymphocytes.
Results
Study design
We evaluated Erk1/2 protein levels, cellular prolifera-
tion, and cellular apoptosis in the brains of BTBR mice,
comparing these to wild-type mice as a control group.
As part of a separate experiment, we previously gener-
ated 410 F2 mice from the crossing of BTBR mice with
B6. We evaluated and scored six different juvenile and
adult social behaviors in all F2 mice [13]. A total of eight
mice at each extreme of the social behavior spectrum
were selected and the expression, and activity levels of
Mapk/Erk in the prefrontal cortex and cerebellum of
these mice were compared (Figure 1). Finally, we com-
pared the Mapk/Erk signaling pathway in the brains and
lymphocytes of the same mice to evaluate the possibility
of using lymphocytes as an indirect surrogate for Erk ac-
tivation in the brain.
The ERK signaling pathway is upregulated in BTBR mice
To evaluate the Erk1/2 signaling pathway, we focused on
Ras, Mek1/2 and Erk1/2 proteins and assessed the abun-
dance of these and their phosphorylated isoforms in the
brains of BTBR and B6 mice using Western blot analysis
(Figure 2). In P0 mice, the relative expression level of
RAS was 0.41 fold higher in BTBR mice compared to
control B6 mice (trend level: P = 0.093). There was no dif-
ference in the total protein level of Erk (t-Erk) between
the two strains (P = 0.930). We also evaluated the activity
level of Erk1/2 by assessing the degree of phosphorylation
of the Thr 202/Tyr 204 amino acids in the activation do-
main in Erk1 and the equivalent residues (Thr 185/Tyr
187) in Erk2. Despite the similarity in total protein levels
for these kinases in BTBR and B6 mice, the relative
amount of phosphorylated extracellular signal-regulated
kinase (p-Erk)/actin in neonatal BTBR mice was 2.78 fold
higher than in B6 mice (P = 0.002). We also evaluated the
levels of p-ERK1 and p-ERK2 separately in BTBR and B6mice, and we found that p-Erk was still elevated in BTBR
compared to B6 mice (p-ERK1: 1.9 fold higher in BTBR,
P = 0.004, p-Erk2: similarly 1.8 fold higher in BTBR,
P <0.001). We also evaluated the kinase Mek, which is
upstream of Erk. No significant difference was detected
between the expression levels of p-MEK or total MEK
levels in these two strains (P ≥0.05) (Western blot lanes of
these experiments are shown in Additional file 1).
Next, we evaluated mice at P30 to determine whether
this signaling pathway shows increased activation tem-
porarily in the newborn period or whether this persists
through the juvenile phase. Ras/actin and p-Erk/actin
levels were significantly increased in P30 BTBR mice
compared to B6 mice (RAS: 3.7 fold higher in BTBR, P =
0.007; p-Erk: 0.71 fold higher in BTBR, P = 0.026), whereas
relative t-Erk levels remained unchanged (P = 0.179). To
take into consideration the effect of total abundance of
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Figure 2 Increased activity levels of Mapk/Erk signaling pathway in BTBR mice. Western blot analysis of eight BTBR versus eight C57BL/6
mice. Brain lysates were evaluated at P0 and P30 time points with antibodies against Ras, t-Erk and p-Erk. Quantitative fold-changes of bands were
assessed, after being normalized to actin levels (A-C). Despite t-Erk levels being unchanged, the mean expression levels of Ras and p-Erk were
significantly increased in BTBR mice at both P0 and P30 using the non-parametric Mann-Whitney U test (*P <0.05, **P <0.005, Bars represent the
mean values, whiskers shows standard deviations).
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(t-Erk/actin) was also evaluated in P0 and P30 mice. In P0
animals, the ratio (p-Erk/actin)/(t-Erk/actin) was 1.59 fold
higher in BTBR mice than in B6 (P = 0.005). However, this
ratio was no longer significant at P30 (P = 0.281). In sum-
mary, these findings demonstrate that activation of the
Erk pathway is elevated in the brains of BTBR mice, par-
ticularly in the newborn period, even though there may be
experience-dependent or other developmental changes in
behavior that correlate with changes in Erk activation in
juvenile and adult mice [16,17].Decreased cellular proliferation in embryonic BTBR mice
Dysregulation of the MAPK/ERK pathway has been impli-
cated in altered neurogenesis or increased apoptosis, de-
pending on the cell type and condition [17-20]. Because
we observed an increase in the Erk signaling pathway, we
wondered whether there might also be differences in
neurogenesis and/or apoptosis in these mice. We there-
fore initially assessed neural cell proliferation in the fore-
brain at both E14 and E17 in BTBR (n ≥6 per age) and
control mice (n ≥6 per age). To evaluate proliferation and
any changes in cell cycle exit, immunohistochemistry with
antibodies targeted to the mitotic marker phospho-
histone H3 (PH3), the cortical radial glial marker Pax6,
and the cortical intermediate progenitor marker Tbr2
were used in combination with the proliferation marker
Ki67 and a 30 minute pulse of the thymidine analogue
EdU to label proliferating cells entering S-phase (Figures 3
and 4). Representative regions of the cortical midline,
neocortex, and ganglionic eminence (GE) were quanti-
fied in both BTBR and control mice. This analysis showed
no differences in cell cycle exit (EdU-positive/Ki67-
negative cells) between BTBR and control mice at either
age (Additional file 2: Figure S2), however regional and
age specific changes in proliferation were evident.Within the cortical midline, we observed a significant
increase (1.19 fold-change, P = 0.0122) in the number of
radial glial cells entering S-phase at E14 (Pax6-positive/
EdU-positive/Ki67-positive cells; Figure 3Q). Interest-
ingly, this increase was not sustained at E17 (Figure 4Q).
In contrast, we observed a decrease (0.59 fold-change,
P = 0.0006) in the number of proliferating intermediate
progenitor cells within the E17 cortical midline (Tbr2-
positive/EdU-positive/Ki67-positive cells; Figure 4Q). This
difference is specifically due to a decrease in the number
of Tbr2-positive cells (0.79 fold-change, P = 0.0175) rather
than a decrease in the total number of EdU-positive cells
(Additional file 2: Figure S2D), suggesting that prolonged
retention of radial glial progenitors at E14 may lead to
a subsequent decrease in the number of intermediate
progenitors at later stages. Within the neocortex, no
significant changes in proliferation were evident at E14
(Figure 3R), however by E17, a marked reduction in
mitotic cells (PH3-positive/EdU-positive/Ki67-positive:
0.18 fold-change, P = 0.0006) and proliferating radial glia
(Pax6-positive/EdU-positive/Ki67-positive cells: 0.90 fold-
change, P = 0.0006) was present (Figure 4R). Within
the GE, we also observed a significant decrease (0.84
fold-change, P = 0.0087) in the number of mitotic cells
throughout the GE at E14 (PH3-positive/EdU-positive/
Ki67-positive cells, Figure 3S), however this difference
was not sustained at E17 (Figure 4O, P; Additional file 2:
Figure S2F). Note that the GE does not express high levels
of Pax6 or Tbr2, compared to cortical structures and thus
these markers cannot be used to define subpopulations of
the GE (Additional file 3: Figure S3). Taken together, these
results suggest that the genetic background of BTBR mice
affects neural cell proliferation differentially throughout
forebrain development, predominantly resulting in de-
creased proliferation relative to controls.
To determine whether apoptosis was affected in a similar
manner, we then evaluated the apoptosis rate in the same
Figure 3 BTBR mice exhibit altered cellular proliferation in the midline and ganglionic eminence at E14. E14 control (A) and BTBR (B)
mice (n ≥6) were injected with EdU 30 minutes prior to sacrifice and immunolabeled for nuclear marker DAPI (white), EdU (green), phospho-histone
H3 (PH3, blue), and Ki67, Pax6, or Tbr2 (red). Cell counts were performed for single, double, and triple-labelled cells, where data for all counts are
shown in Additional file 2: Figure S2. Representative regions from the midline of control (C-E) and BTBR (F-H) mice demonstrate that
BTBR mice have increased incorporation of EdU, particularly into Pax6-positive cells, as quantified in (Q). No difference was evident between
the neocortex of control (I-K) and BTBR mice (L-N, and quantified in R). However, the ganglionic eminence of BTBR mice (P) exhibited decreased
incorporation of EdU compared to control (O), and reduced mitosis as indicated by PH3 staining (quantified in S). Scale bar in B represents
500 μm for A-B. Scale bar in H and P represents 100 μm for C-H and I-P respectively. Mann-Whitney U test for significance: *P <0.05, **P <0.01. Data are
presented as mean ± SEM. (E14: Embryonic day 14; EDU, 5-Ethynyl-2′-deoxyuridine; DAPI, diamidino-2-phenylindole; Pax6: Paired Box 6; Tbr2,T-Box
Brain Protein 2).
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marker cleaved caspase-3 showed no difference in cell
death rates between BTBR and control mice (data notshown). These results suggest that there are developmental
reductions in neural proliferation but no change in apop-
tosis in BTBR mice.
Figure 4 (See legend on next page.)
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Figure 4 BTBR mice exhibit reduced cellular proliferation in the midline and neocortex at E17 corresponding to a reduction in
progenitor cells. E17 control (A) and BTBR (B) mice (n ≥6) were injected with EdU 30 minutes prior to sacrifice and immunolabeled for
nuclear marker DAPI (white), EdU (green), phospho-histone H3 (PH3, blue), and Ki67, Pax6, or Tbr2 (red). Cell counts were performed for
single, double, and triple-labelled cells, where data for all counts are shown in Additional file 2: Figure S2. Representative regions from the midline of
control (C-E) and BTBR (F-H) mice demonstrate that BTBR mice have reduced incorporation of EdU into Tbr2-positive cells, as quantified in (Q).
Furthermore, BTBR mice show reduced incorporation of EdU into mitotic cells (PH3-positive), and radial glia (Pax6-positive) in the neocortex
(L-N) as compared to control animals (I-K, quantified in R). No differences in cellular proliferation were observed in the ganglionic eminence between
control (O), and BTBR mice (P). Scale bar in B represents 500 μm for A-B. Scale bar in J represents 100 μm for E-J. Scale bar in Q represents 100 μm for
K-M, O-Q. Scale bar in R represents 100 μm for N and R. Mann-Whitney U test for significance: ***P <0.001. Data are presented as mean ± SEM. (E17:
Embryonic day 17; EDU, 5-Ethynyl-2′-deoxyuridine; DAPI, diamidino-2-phenylindole; Pax6, Paired Box 6; Tbr2,T-Box Brain Protein 2).
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impairment in social behaviors
We next sought to determine whether increased activity
levels of Mapk/Erk in the brain of BTBR mice were as-
sociated with the abnormal social behaviors of these
mice. We previously developed a cohort of F2 inter-
crossed mice (B6 crossed with BTBR) in attempt to map
the genetics of abnormal social behavior in this strain
[13]. The 410 F2 mice were scored based on the follow-
ing behavioral parameters: total juvenile interaction, ju-
venile approach front, juvenile pushing and crawling,
juvenile nose-to-nose interaction, adult novel mouse
sniffing, and self-grooming. For each social behavior, we
selected the eight mice with the lowest scores and the
eight mice with the highest scores (Figure 1). The me-
dian of each social behavior score was significantly dif-
ferent between the two groups of mice. Expression levels
of p-Erk/actin in the prefrontal cortex were compared
by Western blotting. We found that the degree of Erk
phosphorylation was 2.7 fold higher in F2 mice with low
scores on the ‘approach front’ social assay in comparison
to mice with high scores (P = 0.032) (Figure 5A). This ra-
tio was still significantly different between the two groups
of F2 mice when incorporating total Erk into the equation:
((p-Erk/actin)/(t-Erk/actin); 2.7 fold greater in F2 mice
with low scores, P = 0.037).
A similarly significant difference was observed when
comparing the amount of p-Mek/actin (0.8 fold-change,
P = 0.028), the signaling kinase immediately upstream of
Erk (Figure 5C). However, the ratio of p-Mek/Mek was
not significantly different between the two groups (P =
0.19). As in the parental strains, there was no difference
in the total steady state protein levels of Mek and Erk
molecules between the two groups (t-Mek, P = 0.104;
t-ERK, P = 0.878). (Western blot lanes of these exper-
iments are shown in Additional file 1).
Mice with other impaired social behaviors showed a
trend towards higher p-Erk levels, but these changes
were not statistically significant (Figure 5A). Prior stud-
ies have suggested that, in addition to the prefrontal cor-
tex, the cerebellum may contribute to the development ofsocial behaviors [21]. We therefore evaluated p-Erk levels
in the cerebellum of F2 mice. In contrast to the prefrontal
cortex, no significant differences were detected in the ex-
pression levels of p-Erk in the cerebellum of mice with
low scores in social behaviors in comparison to mice with
high scores (Additional file 4: Figure S1).
MAPK/ERK expression in the brain and lymphocytes
The above findings suggest that p-Erk levels in BTBR
mice are elevated and may correlate with the degree of
social impairment. Given that other mouse models and
human syndromes associated with ASD also show ele-
vated activation of Erk, we sought to assess whether the
elevated p-Erk that we observed in the cerebral cortex of
BTBR mice was also seen in other tissue types, in par-
ticular lymphocytes, given their ready accessibility by
venipuncture. We therefore isolated proteins from the
brain and splenic lymphocytes of four BTBR, four B6,
and eight newly bred F2 mice (from a cross of BTBR
and B6), which should have a mixture of BTBR and B6
gene alleles and thus phenotypically should span the
levels seen in the parental strains. Expression and activ-
ity levels of Mek and Erk were evaluated in these mice,
using Western blot analysis, and normalized by actin
levels. This analysis demonstrated a positive correlation
between the amounts of p-Mek as well as p-Erk levels in
the brain versus lymphocytes (p-Mek: Spearman’s rank
correlation coefficient (r) = 0.846 P <0.001; p-ERK: r =
0.552, P = 0.017). Total expression levels of Mek and
Erk were also significantly correlated between brain tissue
and lymphocytes (t-Mek: n = 16, r = 0.700, P = 0.004;
t-ERK: n = 16, r = 0.521, P = 0.046) (Figure 6).
Discussion
In this study, we observed increased activation of the Ras/
Erk pathway in the brains of BTBR mice, a strain that has
social and behavioral deficits that may have relevance to
ASDs [13]. Increased p-Erk levels in the newborn BTBR
strain are consistent with a prior study that evaluated this
pathway in BTBR mice [14]. However, this increased acti-
vation of Erk was less pronounced in adolescent BTBR
A)         B) Juvenile approach front
*
*
Figure 5 Association between the degree of MAPK/ERK activity in the prefrontal cortex and social behavioral score was observed in F2
mice. Western blot analysis of extracted proteins from the prefrontal cortex of eight mice with the lowest scores and eight mice with the highest
scores of five different social behaviors were using the p-ERK antibody. A) Quantitative fold-changes of bands were assessed, after being normalized
by actin levels. Mean p-ERK levels were increased significantly in F2 mice that performed poorly in the ‘juvenile approach front’ social assay using the
non-parametric Mann-Whitney U test. B) Other Mapk/Erk signaling pathway proteins including Ras, t-Mek, p-Mek, and t-Erk were compared in mice
with low scores on ‘juvenile approach front’ social assay versus mice with high scores, using Western blot analysis. p-Mek levels were also significantly
amplified in mice with low juvenile approach front scores. (*P <0.05, bars represent mean values, whiskers show standard deviations). (Erk, Extracellular
signal-regulated kinase; p-Erk, phosphorylated extracellular signal-regulated kinase; Mapk, Mitogen-activated protein kinase; Mek, Mitogen-activated
protein kinase kinase; p-Mek, phosphorylated Mitogen-activated protein kinase kinase).
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the brains of BTBR mice are not increased compared to
B6 mice. Thus, we hypothesize that the possible contribu-
tion of the Mapk/Erk signaling pathway to neurocognitive
impairment in this mouse model of autism occurs through
posttranslational modification of the Erk pathway. In sup-
port of this hypothesis, we showed that activation of the
Erk signaling pathway, but not total Erk protein levels in
prefrontal cortex, is associated with the degree of social
impairment in intercrossed F2 mice with a mixed genetic
background.
How might a change in the levels of ERK activation
lead to behavioral abnormalities? Increased activation
levels of MAPK/ERK in neurons have been shown to se-
lectively increase pools of mRNAs encoding adhesion
molecules and scaffolding proteins [22,23]. Increased ex-
pression levels of these molecules can change the bal-
ance between excitatory and inhibitory synapses [23],which has been suggested as a likely basis for impaired
cognition and possibly for ASD [24,25]. In support of these
hypotheses, Seese et al. showed a negative correlation be-
tween the intensity of synaptic p-Erk1/2 immunolabeling
and cognitive function across BTBR mice [26]. This is
clearly a complex issue, as the RAS/ERK signaling path-
way is embedded in a network of other signaling path-
ways. ERK1/2 also has more than 70 different cytoplasmic
and nuclear substrates, regulating many fundamental cel-
lular processes. It is possible that each of the different pro-
teins in this network has a cumulative effect on cognitive
and behavioral impairments. However, more focused ex-
periments are required to evaluate the role of each kinase
individually. In contrast to the prefrontal cortex, when we
evaluated the cerebellum of F2 mice, p-Erk levels were
similar between mice with high and low social behavior
scores, suggesting that the cerebellum may not be a focus
of behavioral changes in this mouse strain. However,
A)
t-Mek/Acn t-Erk/Acn
p-Mek/Acn p-Erk/Acn
P-Value:0.004
R: 0.700 P-Value:0.046R: 0.521
P-Value:0.0001
R: 0.846
P-Value:0.01
R: 0.552
B)
Figure 6 Correlation between expression levels of MAPK/ERK in the brain and in lymphocytes. Proteins were extracted from the brains
and lymphocytes of four BTBR, four B6, and eight F2 mice. The expression and activity levels of MEK and ERK were compared between the brain
and lymphocytes of each mouse, using Western blot analysis. A) The phosphorylation levels of MEK and ERK in the brain and lymphocytes of
mice were significantly correlated using Spearman’s rank correlation coefficient analysis. B) Significant correlation in total expression levels of Mek
and Erk proteins between the brains and lymphocytes of mice. BTBR: green dot, B6: red dot, F2: blue dot. (Erk, Extracellular signal-regulated kinase;
p-Erk, phosphorylated extracellular signal-regulated kinase; Mapk, Mitogen-activated protein kinase; Mek, Mitogen-activated protein kinase kinase;
p-Mek, phosphorylated Mitogen-activated protein kinase kinase).
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F2 mice, we cannot rule out alpha or beta errors in our
preliminary findings.
Because the MAPK/ERK pathway activation has been
shown in many cell types to be central for cell division
and differentiation, we evaluated whether BTBR mice
had, in addition to elevated p-Erk, changes in cell prolif-
eration and apoptosis in the developing forebrain. Evalu-
ation of these parameters during a critical window of
cerebral cortex development revealed distinct spatio-
temporal changes in proliferation, but not apoptosis. De-
creased cellular proliferation in the cerebral cortex
throughout this developmental period is consistent with
other studies that reported a robust reduction in neuro-
genesis in adult BTBR mice [27], which also lead to de-
creased brain volume and cerebral white matter in this
strain [28]. To explore the role of Mapk/Erk on neural
cell proliferation, Yang et al. overexpressed c-Raf in cul-
tured cortical neurons. They observed impairment in
neuronal cell differentiation and maturation and un-
changed apoptosis in the presence of amplified Mapk/
Erk, which is consistent with our findings [19]. However,
the role of the Mapk/Erk pathway in regulating neuronal
cell division and maturation is complex, as other studies
have demonstrated that decreased Mapk/Erk activation
can also disrupt progenitor proliferation [29-31]. Indeed,it is possible that any change from a homeostatic bal-
ance in this pathway may alter cognition and behavior.
However, we were unable in this study to directly compare
proliferation with behavior, so it is still remains possible
that this change represents strain-to-strain variation with-
out correlation with behavior.
In addition to these findings in the developing brain,
we also found that the degree of activation of the Erk
pathway directly correlated when comparing brain tissue
to lymphocytes, suggesting that biological correlates of so-
cial impairment could be measured in peripheral blood.
Based on these findings in a mouse strain, we speculate that
this pathway could be dysregulated in the lymphocytes of
autistic patients. Further investigation will be required to
assay the levels of MAPK/ERK in the lymphocytes of indi-
viduals with autism and whether this could serve as a
framework for developing a potential biomarker for autism.
Conclusion
Our observations in BTBR mice as a preclinical model
of autism, suggest that dysregulation of the ERK signal-
ing pathway in CNS may be an important mediator of
social behavior particularly in prefrontal cortex, In
addition, measuring activation of this pathway in periph-
eral lymphocytes may serve as a surrogate marker for
CNS ERK activity, and possibly autistic behavior.
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Additional file 1: Figure S4. Evaluating the expression levels of
proteins with Western blot analysis. A) Western blot lanes of six BTBR
versus six C57BL/6 mice. Brain lysates were evaluated at P0 and P30 time
points with antibodies against RAS, p-ERK and actin. B) Western blot lanes
of extracted proteins from the prefrontal cortex of eight F2 with
the lowest scores and eight mice with the highest scores in the ‘juvenile
approach front’. Brain lysates were evaluated with antibodies against RAS,
t-MEK, p-MEK and p-ERK. C) Western blot lanes of extracted proteins from
the prefrontal cortex of eight mice with the lowest scores and eight
mice with the highest scores in ‘Juvenile nose-to-nose’, ‘Juvenile
mouse-to-mouse sniff’ and ‘Total juvenile interaction’ social behaviors,
using the p-ERK and actin antibodies.
Additional file 2: Figure S2. Quantification of cellular proliferation at
E14 and E17 indicate that BTBR mice have altered neurogenesis. E14 and
E17 control (n = 6 per age) and BTBR mice (n ≥6 per age) were injected
with EdU 30 minutes prior to sacrifice and labelled for either PH3,
Pax6, or Tbr2 in combination with Ki67 and EdU. Cell counts from
representative regions of the cortical midline (A-B), neocortex (C-D),
and ganglionic eminence (E-F) were performed for single, double,
and triple-labelled cells. Data are represented as mean ± SEM. Mann-Whitney
U test for significance: *P <0.05, **P <0.01, ***P <0.001.
Additional file 3: Figure S3. The ganglionic eminence of BTBR and
control mice expresses low levels of the progenitor markers Tbr2 and
Pax6. E14 control (A), E14 BTBR (B) mice, E17 control (C), and E17 BTBR
mice (D) were injected with EdU 30 minutes prior to sacrifice and
immunolabelled for nuclear marker DAPI (white or blue), EdU (green),
and either Pax6 or Tbr2 (red). High power images (A’-D”) demonstrate
that neither Tbr2 nor Pax6 are expressed at detectable levels in the
ganglionic eminence. Scale bar in B and D represents 500 μm for A, B
and C, D respectively. Scale bar in D” represents 100 μm for A’-D”. n ≥6
for all conditions.
Additional file 4: Figure S1. The association between degree of Mapk/
Erk signaling pathway activity in the cerebellum and social behavior
scores in F2 mice. A) Proteins were isolated from the cerebellum of
eight F2 mice on the extremities of each social behavior. p-Erk levels were
evaluated in two groups of mice with lowest and highest scores of each
social behavior, using Western Blot analysis. B) Quantitative fold-change in
p-Erk have been shown for each social behaviors, after being normalized by
actin. No significant change in p-Erk levels were detected in comparing
mice with low social behavioral scores and mice with high scores.
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